GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ...

Goldman Sachs said Monday that GSK (NYSE:GSK) is set for a 'positive surprise' this week as a CDC Advisory Committee is scheduled to discuss whether to broaden the recommendation for Arexvy ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...

vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court. GSK and Pfizer said in the filing, opens new tab that they ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales. The respiratory ...

The ongoing phase I revaccination trial in the U.S. is enrolling up to 160 older adults (60-85 years) who previously received an initial dose of GSK’s RSV vaccine (Arexvy) at least 2 seasons prior, ...

The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...

The massive trial saw 24,972 people aged 60 or older get either the RSVPreF3 OA vaccine (brand name Arexvy, by GSK) or a placebo, administered in 275 clinics across 17 countries across five ...